Affiliation: Pfizer Global Research and Development
- Oxidative stress in obstructive sleep apnoeaAnna Svatikova
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Eur Heart J 26:2435-9. 2005..We tested the hypothesis that measures of oxidative stress are increased in otherwise healthy subjects with OSA when compared to closely matched OSA-free control subjects...
- Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity ParadoxRobert Wolk
Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN Pfizer Inc, Groton, CT Electronic address
Mayo Clin Proc 91:858-66. 2016..To evaluate the cardiovascular (CV) prognostic value of adipokines in a large prospective cohort of patients participating in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial...
- Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trialRobert Wolk
Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, USA Pfizer Global Research and Development, Pfizer Inc, Groton, USA
Eur J Prev Cardiol 23:50-8. 2016....
- Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjectsR Wolk
Global Research and Development, Pfizer, New London, Connecticut, USA
Clin Pharmacol Ther 86:430-7. 2009..No changes in blood pressure (BP) were observed. The possible effects of higher CP-800,569 doses on aldosterone and cortisol levels could not be excluded. The results of this study may be useful in CP-800,569 dose selection...
- Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertensionRobert Wolk
Pfizer Global Research and Development, Pfizer Inc, New London, CT 06320, USA
Hypertension 53:1091-7. 2009..In conclusion, PF-00489791 causes a clinically meaningful and sustained BP lowering in patients with hypertension. It is generally safe and well tolerated at the clinically efficacious doses...
- Sleep and the metabolic syndromeRobert Wolk
Cardiovascular Metabolic Diseases, Pfizer Global Research and Development, Eastern Point Road, MS 8260 2506, Groton, CT 06340, USA
Exp Physiol 92:67-78. 2007....
- Obesity-related cardiovascular disease: implications of obstructive sleep apneaR Wolk
Department of Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55902, USA
Diabetes Obes Metab 8:250-60. 2006..Identification of the OSA-dependent and OSA-independent pathways in the cardiovascular pathophysiology of obesity may hold clinical and therapeutic promise...
- Obesity, sleep apnea, and hypertensionRobert Wolk
Mayo Clinic, Rochester, Minn, USA
Hypertension 42:1067-74. 2003....
- Interactions between obstructive sleep apnea and the metabolic syndromeAnna Svatikova
Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA
Curr Diab Rep 5:53-8. 2005....
- Association between plasma adiponectin levels and unstable coronary syndromesRobert Wolk
Division of Cardiovascular Diseases, Mayo Clinic, 1216 Second Street SW, Rochester, MN 55902, USA
Eur Heart J 28:292-8. 2007..This study evaluated the association between adiponectin and ACS...
- Familial premature coronary artery disease mortality and obstructive sleep apneaApoor S Gami
Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Chest 131:118-21. 2007..A family history of premature CAD and related mortality is an independent risk factor for the development of CAD. We hypothesized that OSA is associated with a family history of premature mortality from ischemic heart disease...
- Microarray studies of genomic oxidative stress and cell cycle responses in obstructive sleep apneaMichal S Hoffmann
Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Antioxid Redox Signal 9:661-9. 2007..These overnight changes in OSA patients are suggestive of activation of several mechanisms to modulate, and adapt to, increased ROS developing in response to the frequent episodes of intermittent hypoxia...
- Sleep and cardiovascular diseaseRobert Wolk
Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Curr Probl Cardiol 30:625-62. 2005..Further understanding of specific pathophysiological pathways linking sleep disorders to cardiovascular disease is important for developing therapeutic strategies and may have important implications for cardiovascular chronotherapeutics...
- Cardiovascular consequences of obstructive sleep apneaRobert Wolk
Mayo Clinic, Department of Medicine, Division of Cardiovascular Diseases and Division of Hypertension, 200 First Street Southwest, Rochester, MN 55905, USA
Clin Chest Med 24:195-205. 2003..g., central obesity, age, and male gender). Treating sleep apnea may help to achieve better clinical control in these diseases and may improve long-term cardiovascular prognosis...
- Sleep-disordered breathing and cardiovascular diseaseRobert Wolk
Mayo Clinic, Rochester, MN 55902, USA
Circulation 108:9-12. 2003
- Serum amyloid a in obstructive sleep apneaAnna Svatikova
Mayo Foundation, Rochester, Minn, USA
Circulation 108:1451-4. 2003..Serum amyloid A (SAA) protein has recently been linked to the development of atherosclerosis, stroke, diabetes, and dementia. We tested the hypothesis that plasma SAA levels are increased in otherwise healthy subjects with OSA...
- Plasma adrenomedullin and obstructive sleep apneaRobert Wolk
Mayo Clinic, Rochester, Minnesota, USA
Am J Hypertens 17:74-6. 2004..Obstructive sleep apnea (OSA) is associated with hypertension. The vasorelaxing peptide adrenomedullin (ADM) may counteract effects of OSA-induced release of vasopressor substances...
- Circulating free nitrotyrosine in obstructive sleep apneaAnna Svatikova
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Am J Physiol Regul Integr Comp Physiol 287:R284-7. 2004..This observation suggests that repetitive hypoxemia during OSA does not result in increased NO-mediated oxidative/nitrosative stress in otherwise healthy subjects with OSA...
- Cardiac troponin T in obstructive sleep apneaApoor S Gami
Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Chest 125:2097-100. 2004..We tested the hypothesis that severe nocturnal hypoxia in patients with OSA causes myocyte necrosis as evidenced by increases in cardiac troponin T...
- Plasma homocysteine in obstructive sleep apnoeaAnna Svatikova
Division of Cardiovascular Disease, Mayo Clinic and Mayo Foundation, 200 1st St SW, Rochester, MN 55901, USA
Eur Heart J 25:1325-9. 2004..We hypothesised that plasma homocysteine would be higher in OSA patients than in control subjects, would increase further during sleep, and decrease after treatment with continuous positive airway pressure (CPAP)...
- Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apneaRobert Wolk
Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Mayo Foundation, St Mary s Hospital, DO 4 350, 1216 Second Street SW, Rochester, MN 55902, USA
Obes Res 13:186-90. 2005..The purpose of the study was to investigate whether OSA affected plasma levels of adiponectin, which might help explain OSA-associated cardiovascular morbidity...
- Elevated C-reactive protein in patients with obstructive sleep apneaAbu S M Shamsuzzaman
Mayo Clinic Rochester, Rochester, MN 59905, USA
Circulation 105:2462-4. 2002..Inflammatory processes associated with OSA may contribute to cardiovascular morbidity in these patients. We tested the hypothesis that OSA patients have increased plasma C-reactive protein (CRP)...